Abatacept Trial Concludes With Favorable Results In JM Treatment

Abatacept Trial concludes with favorable results in JM treatment

A clinical trial treating patients with juvenile myositis with the drug abatacept resulted in lower disease activity and clinically significant responses in most patients. The trial was conducted at the Cure JM Center of Excellence at George Washington University, and preliminary results were presented at the Global Conference on Myositis.

Abatacept was generally well tolerated with minimal side effects, and the preliminary data suggest that abatacept may be beneficial in the treatment of hard-to-treat JM patients. Importantly, patients using abatacept improved at the same time prednisone dosage was reduced.  

The ten JM patients enrolled in the pilot study were between the ages of seven and 17, and all had moderate disease activity and moderately decreased functional disability. Five of the ten patients met the definition of improvement at week 12 of the trial, and nine met the definition by week 24. At week 24, three of the ten patients saw major improvement, four saw moderate improvement, and two saw minimal improvement when using Core Set Measures against a scale utilized by the International Myositis Assessment and Clinical Studies Group (IMACS).  

When assessing improvements in Core Set Measures against a similar scale used by the Pediatric Rheumatology International Trials Organization (PRINTO), seven of the nine improved patients saw major improvements in their scores. One patient was discontinued from the trial due to worsening interstitial lung disease.

“These results are preliminary but are certainly very encouraging,” said Dr. Rodolfo Curiel, the trial’s principal investigator. 

“We have much more data to assess before we publish the results, yet the pilot study showed that patients with refractory JDM treated with abatacept resulted in lower disease activity and clinically significant responses in the majority of patients.” Dr. Curiel is the Director of the Cure JM Center of Excellence at George Washington University.

Parrish’s Story

We would like to introduce a one-of-a-kind, competitive, and determined young man, named Parrish. His story of resiliency and hope is one that will resonate with many of us in the Cure JM family. Parrish faced many challenges in his journey with JM, but found hope and support in his family and the Cure JM community. We are pleased to now share his experience to help others facing the same struggles during Myositis Awareness Month.

Balancing Work and Caregiving: Strategies for Working Parents of Children with Juvenile Myositis

Balancing the demands of a career with the responsibilities of caregiving is a challenging task for any parent. For those with a child diagnosed with juvenile myositis (JM), a rare autoimmune disease affecting children, the challenge is heightened. Juggling work commitments while providing the necessary care and support for a child with JM can be taxing. In this article, we hope to provide you with a few effective strategies and insights to help working parents navigate this delicate balance.

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.

Cure JM supports families, patients, and the juvenile myositis research community.

Interested in DIY fundraising but need help?

We’re here to help!

To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.